Trial Profile
A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALLY ADVANCED OR METASTATIC) TRIPLE-NEGATIVE BREAST CANCER
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Capecitabine; Carboplatin; Gemcitabine
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpassion132
- Sponsors Roche
- 09 Feb 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 24 Nov 2023 Planned number of patients changed from 572 to 597.
- 14 Aug 2023 Status changed from recruiting to active, no longer recruiting.